** Shares of telehealth firm Hims & Hers Health HIMS.N fall 6.61% to $39.11 premarket
** Co sees Q2 revenue to be between $530 million and $550 million, below estimates of $564.6 million - data compiled by LSEG
** HIMS expects onetime quarter-over-quarter revenue drop in Q2, as it transitions subscribers previously on commercially available dosages of Novo Nordisk's NOVOb.CO semaglutide to options on its or other platforms by end of quarter
** Reaffirms full-year revenue forecast of $2.3 billion to $2.4 billion
** We suspect that the re-affirmed 2025 and new Q2 forecast is likely "conservative," brokerage BTIG says
** Q1 revenue of $586.0 million beats estimates of $538.2 million
** Up to last close, stock up ~73% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。